×
0 0 0 0 0 0 -0.0111731843575418 0.00558659217877094
Stockreport

Ziopharm inks new license deal with Intrexon for cancer platforms; shares up 10% premarket [Seeking Alpha]

Intrexon Corp (XON)  More Company Research Source: Seeking Alpha
Last intrexon corp earnings: 11/8 04:10 pm Check Earnings Report
US:NYSE Investor Relations: investors.dna.com
PDF Ziopharm Oncology (NASDAQ: ZIOP ) enters into a new all-encompassing license agreement with Intrexon's (NASDAQ: XON ) Precigen for the rights to its Controlled IL-12 and Sleeping Beauty (SB) T-cell receptor (TCR) platform technologies for the potential treatment of solid tumors. Under the terms of the deal, Ziopharm will have exclusive development rights to SB and TCRs targeted to neoantigens and public antigens. Precigen's Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) related to SB-generated T cells expressing TCRs to target neoantigens buried within solid tumors will be transferred to Ziopharm who will maintain the exclusive relationship with the NCI for this program. Ziopharm will add the rights to pursue next-generation viral technologies using Precigen's RheoSwitch gene switch while continuing the advancement of its CD19-specific chimeric antigen receptor (CAR) program and retaining the rights to a second unnamed CA [Read more]

IMPACT SNAPSHOT EVENT TIME: XON
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
XON alerts
from News Quantified
Opt-in for
XON alerts

from News Quantified
Opt-in for
XON alerts

from News Quantified